Peptides for activation and inhibition of δPKC

Details Peptides for activation and inhibition of δPKC Peptides for activation and inhibition of δPKC

2007-04-30

2010-12-14

Swope, Sheridan (Department: 1652)

Chemistry: natural resins or derivatives; peptides or proteins;

Peptides of 3 to 100 amino acid residues

Reexamination Certificate

active

07851586

ABSTRACT:
Peptides able to inhibit or activate the translocation or function of δPKC are identified. Administration of the peptides for protection or enhancement of cell damage due to ischemia is described. Therapeutic methods to reduce damage to cells or to enhance damage to cells due to ischemia are also described, as well as methods for screening test compounds for δPKC-selective agonists and antagonists.

REFERENCES:
patent: 4708871 (1987-11-01), Geysen
patent: 5776716 (1998-07-01), Napolitano et al.
patent: 5783405 (1998-07-01), Mochly-Rosen et al.
patent: 6165977 (2000-12-01), Mochly-Rosen
patent: 6664040 (2003-12-01), Sherman et al.
patent: 6855693 (2005-02-01), Mochly-Rosen et al.
patent: 7265092 (2007-09-01), Li
patent: 7563772 (2009-07-01), Mochly-Rosen et al.
patent: 2004/0204364 (2004-10-01), Mochly-Rosen et al.
patent: 2008/0075706 (2008-03-01), Li
patent: 2009/0062208 (2009-03-01), Mochly-Rosen et al.
patent: 2009/0075901 (2009-03-01), Mochly-Rosen et al.
patent: 2009/0186814 (2009-07-01), Ikeno et al.
patent: 2009/0192089 (2009-07-01), Mochly-Rosen et al.
patent: WO 97/14038 (1997-04-01), None
patent: WO-2009/029678 (2009-03-01), None
Galye et al, Identification of regions in interleukin-1 alpha important for activity. J Biol Chem. Oct. 15, 1993;268(29):22105-11.
Whisstock et al, Prediction of protein function from protein sequence and structure. Q Rev Biophys. Aug. 2003;36(3):307-40. Review.
Chen et al, Opposing cardioprotective actions and parallel hypertrophic effects of delta PKC and epsilon PKC. Proc Natl Acad Sci U S A. Sep. 25, 2001;98(20):11114-9. Epub Sep. 11, 2001.
Issued—Patents—AA Sherman et al, from US6664040, SEQ ID No. 4 (priority date May 23, 2000). Alignment with SEQ ID No. 9.
USPTO in house BLAST search with NP—057853 performed Dec. 10, 2009.
Chen et al., Circulation (2000) 102(18 Suppl. II):120.
Chen et al., PNAS USA (1999) 96(22):12784-12789.
Chen et al., PNAS USA (2001) 98(20):11114-11119.
Csukai et al., Pharmacological Research (1999) 39(4):253-259.
Inagaki et al., Circulation (2000) 101(7):797-804.
Inagaki et al., Circulation (2003) 108(7):869-875.
Inagaki et al., Circulation (2003) 108(19):2304-2307.
Johnson et al., Journal of Biological Chemistry (1996) 271(40):24962-24966.
Miettinen et al., J. Neurosci. (1996) 16(19):6236-6245.
Miyawaki et al., Circulation Res. (1997) 80(6):790.
Mochly-Rosen, Science (1995) 268:247-251.
Mochly-Rosen, PNAS USA (1991) 88:3997-4000.
Nishikawa et al., Journal of Biological Chemistry (1997)272(2):952-960.
Shizukuda et al., Circulation (1999) 100(18):1909-1916.
Souroujon et al., Nature Biotechnology (1998) 16(10):919.
Supplementary European Search Report for EP 01 99 5483, mailed on Dec. 21, 2004, 7 pages.
Way et al., Trends in Pharmacological Sciences (2000) 21(5):181-187.
Yoshida et al., Biochimica et Biophysica Acta (1999) 14:230-238.
Armstrong, S., J. M. Downey, et al. (1994). “Preconditioning of isolated rabbit cardiomyocytes: induction by metabolic stress and blockade by the adenosine antagonist SPT and calphostin C, a protein kinase C inhibitor.”Cardiovasc Res28(1): 72-7.
Baler et al., J. Biol. Chem. (1993) 268:4997-5004.
Brew, E. C., M. B. Mitchell, et al. (1995). “Role of bradykinin in cardiac functional protection after global ischemia-reperfusion in rat heart.”Am J Physiol269(4 Pt 2): H1370-8.
Colbert et al., J. Clin. Invest. (1997) 100:1958.
Csukai et al., (1995) 9thInternational Conference on Second Messengers and Phosphoproteins ,112.
Csukai, M., C. H. Chen, et al. (1997). “The coatomer protein beta'-COP, a selective binding protein (RACK) for protein kinase Cepsilon.”J Biol Chem272(46): 29200-6.
Disatnik, M. H., G. Buraggi, et al. (1994). “Localization of protein kinase C isozymes in cardiac myocytes.”Exp Cell Res210(2): 287-97.
Dorn, G. W., 2nd, M. C. Souroujon, et al. (1999). “Sustained in vivo cardiac protection by a rationally designed peptide that causes epsilon protein kinase C translocation.”Proc Natl Acad Sci U S A96(22): 12798-803.
Gray, M. O., J. S. Karliner, et al. (1997). “A selective epsilon-protein kinase C antagonist inhibits protection of cardiac myocytes from hypoxia-induced cell death.”J Biol Chem272(49): 30945-51.
Guo et al., Am. J. Physiol. (1998) 275:H1375-H1387.
Hu, K. and S. Nattel (1995). “Mechanisms of ischemic preconditioning in rat hearts Involvement of alpha 1B-adrenoceptors, pertussis toxin-sensitive G proteins, and protein kinase C.”Circulation92(8): 2259-65.
Johnson, J. A. and D. Mochly-Rosen (1995). “Inhibition of the spontaneous rate of contraction of neonatal cardiac myocytes by protein kinase C isozymes. A putative role for the epsilon isozyme.”Circ Res76(4): 654-63.
Johnson, J. A., M. O. Gray, et al. (1996). “An improved permeabilization protocol for the introduction of peptides into cardiac myocytes. Application to protein kinase C research.”Circ Res79(6): 1086-99.
Liu, Y., A. Tsuchida, et al. (1995). “Pretreatment with angiotensin II activates protein kinase C and limits myocardial infarction in isolated rabbit hearts.”J Mol Cell Cardiol27(3): 883-92.
Mackay, K. and D. Mochly-Rosen (1999). “An inhibitor of p38 mitogen-activated protein kinase protects neonatal cardiac myocytes from ischemia.”J Biol Chem274(10): 6272-9.
Maier et al., Stroke (1998) 29:2171-2180.
Mitchell et al., Circulation (1993) 88:1633.
Mitchell, M. B., X. Meng, et al. (1995). “Preconditioning of isolated rat heart is mediated by protein kinase C.”Circ Res76(1): 73-81.
Mitchell, D. J., D. T. Kim, et al. (2000). “Polyarginine enters cells more efficiently than other polycationic homopolymers.”J Pept Res56(5): 318-25.
Mochly-Rosen, D., C. J. Henrich, et al. (1990). “A protein kinase C isozyme is translocated to cytoskeletal elements on activation.”Cell Regul1(9): 693-706.
Mochly-Rosen, D., H. Khaner, et al. (1991). “Intracellular receptors for activated protein kinase C. Identification of a binding site for the enzyme.”J Biol Chem266(23): 14866-8.
Mochly-Rosen, D., G. Wu, et al. (2000). “Cardiotrophic effects of protein kinase C epsilon: analysis by in vivo modulation of PKCepsilon translocation.”Circ Res86(11): 1173-9.
Murry, C. E., R. B. Jennings, et al. (1986). “Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium.”Circulation74(5): 1124-36.
Osada et al., Molec. Cell. Biol. (1992) 12:3930.
Papadopoulos and Hall, J. Cell. Biol. (1989) 108:553-567.
Pitcher, J. A., J. Inglese, et al. (1992). “Role of beta gamma subunits of G proteins in targeting the beta-adrenergic receptor kinase to membrane-bound receptors.”Science257(5074): 1264-7.
Rothbard, J. B., S. Garlington, et al. (2000). “Conjugation of arginine oligomers to cyclosporin A facilitates topical delivery and inhibition of inflammation.”Nat Med6(11): 1253-7.
Ron, D., C. H. Chen, et al. (1994). “Cloning of an intracellular receptor for protein kinase C: a homolog of the beta subunit of G proteins.”Proc Natl Acad Sci U S A91(3): 839-43.
Ron, D., J. Luo, et al. (1995). “C2 region-derived peptides inhibit translocation and function of beta protein kinase C in vivo.”J Biol Chem270(41): 24180-7.
Ron, D. and D. Mochly-Rosen (1995). “An autoregulatory region in protein kinase C: the pseudoanchoring site.”Proc Natl Acad Sci U S A92(2): 492-6.
Saito et al., PNAS USA (1989) 86:3409-3413.
Schultz, J. E., A. K. Hsu, et al. (1996). “Morphine mimics the cardioprotective effect of ischemic preconditioning via a glibenclamide-sensitive mechanism in the rat heart.”Circ Res78(6):1100-4.
Smith, B. L. and D. Mochly-Rosen (1992). “Inhibition of protein kinase C function by injection of intracellular receptors for the enzyme.”Biochem Biophys Res Commun188(3): 1235-40.
Speechly-Dick, M. E., M. M. Mocanu, et al. (1994). “Protein kinase C. Its role in ischemic preconditio

Affiliated with

Also associated with

Rating

Peptides for activation and inhibition of δPKC does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Peptides for activation and inhibition of δPKC, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Peptides for activation and inhibition of δPKC will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4182020